Two papers: HPV vaccines uniquely block infection, while severe viral pneumonia primes neutrophils that accelerate lung cancer.
The literature says vaccines prevent disease but permit infection, because the memory response is a few days delayed, so the virus gets in and replicates. Very high antibody or T-cell levels shortly after vaccination might block infection, but not over the long term. HPV is the exception.
Answered around 11:30In the 2011 Guanacaste, Costa Rica community-based randomized trial, infection measured by PCR because the virus is hard to grow, efficacy against HPV 16 and 18 was 90 percent, less than the claim it was cited for, but at year four it reached 100 percent, getting better with time.
Answered around 17:07In the cervix the mucosal epithelium is layered, and the virus must reach the basal keratinocytes, which it cannot do without a break in the mucosa. It binds heparin sulfate proteoglycans on the basement membrane, which exposes the minor capsid protein L2; furin cleaves it, and further changes let L1 bind its receptor.
Answered around 18:11Because entry takes hours rather than minutes. Antibodies added three hours after the virus had attached still neutralized, and at eighteen hours post-attachment there was still some inhibition of infectivity, unusual since most viruses bind and are taken in quickly by endocytosis. That slow, multi-step entry is the opening.
Answered around 19:19One mechanism is that the antibody pushes the particle off the cell surface, inducing shedding. Another brings it inside the cell where it is degraded, though not through TRIM21, which is not involved here. A third simply retains the particle on the surface. Different antibodies use these in different combinations.
Answered around 30:45Years. There are long-lived and short-lived plasma cell subtypes in different anatomic locations. Once a cell has differentiated all the way to a plasma cell it cannot divide again or become anything else; it just produces antibody. But some memory cells can differentiate into plasma cells.
Answered around 35:18In the Epic Cosmos medical records, severe COVID requiring hospitalization was associated with a 1.24-fold higher lung cancer hazard after adjustment for comorbidities, and those patients had the highest cumulative hazard. Prior non-severe infection was instead associated with a moderate decrease in lung cancer diagnoses.
Answered around 52:30Yes. Two doses of spike-encoding mRNA vaccine substantially reduced tumor burden compared with mock-immunized mice, and an inactivated influenza vaccine did the same. The vaccine appears to work by preventing severe disease: a low dose causing only moderate disease did not increase tumor burden.
Answered around 56:49Neutrophils. Clustering showed clusters 1, 5 and 6 highly enriched for Siglec-F, a marker of pro-tumor neutrophils, which sit in the lung parenchyma. Implanting tumor cells together with Siglec-F-high neutrophils gave a bigger tumor mass than Siglec-F-low ones, and vaccinated mice lacked them.
Answered around 1:02:14Partly. An antibody to Ly6G plus reparixin, which blocks chemokine receptor 2 signaling, given before tumor inoculation, reduced lung neutrophils, decreased tumor burden and improved survival, though not completely. Adding anti-PD-L1 to the neutrophil blockade significantly suppressed tumor burden in infected tumor-bearing mice.
Answered around 1:15:01“it is, it is the only vaccine that prevents infection.”
“So this is, I think we've mentioned this before, This is vaccinologists fooling Mother Nature.”
“So neutrophils are innate immune cells that basically largely work by phagocytosis.”
“Well, look, folks, if you don't want to get lung cancer after respiratory virus infection, just get a vaccine.”
“This Week in Virology Episode 1309.” https://traffic.libsyn.com/secure/twiv/TWiV1309.mp3. Transcript summary by WhipScribe, https://whipscribe.com/transcript-pages/this-week-in-virology-episode-1309.html.